Do you know why?
Due to busy life-styles, low-fibre diets can cause a significant decrease in the production of butyric acid. Low-fibre diets are also frequently recommended to patients with irritable bowel syndrome or inflammatory bowel disease due to reduced tolerance.
Decreased production of butyric acid, which is the main energetic material for colon cells, may impair intestinal functions. As a consequence, symptoms such as diarrhoea, flatulence, abdominal pain, peristalsis abnormalities, including gurgling and change of bowel movements, may occur. The improper intestinal function may favour the disturbance of microbiota balance in the large intestine that helps the pathogenic bacteria to colonise, and increases unpleasant symptoms.
The intestinal epithelium is a very delicate tissue because its renewal is very dynamic. Healthy epithelium forms a barrier that protects against penetration of microorganisms and toxins and of other harmful substances from the intestinal contents into the body. The intestinal mucous membrane produces adequate amounts of mucus which is needed for beneficial bacteria to grow and produce numerous important compounds such as vitamins and small molecules called short chain fatty acids (SCFAs) which are important as energy sources for our large bowel.
Among the SCFAs, butyric acid plays the most important role in maintaining intestinal health as it is the major source of energy for colonocytes and having a number of important functions.
Today, most therapies available to patients with irritable bowel syndrome are often suboptimal. Pharmaceutical treatment for irritable bowel syndrome remains a major problem. The therapeutic efforts mainly target the disease symptoms but not its causes. The efficacy of IBS treatments does not stand up to the expectations of patients and physicians. Therefore, both patients and HCPs look forward to more effective medications and complementary solutions that could improve the outcomes in this disease. Energast, which contains 150mg of sodium butyrate, has been clinically proven to help in IBS management.
Butyric acid is proven to have a positive impact on the intestinal health with its potentially beneficial mechanism of action. It is one of short-chain fatty acids (SCFAs), a natural substance being produced in bacterial fermentation of complex carbohydrates. Butyric acid plays a crucial role in maintaining the proper function of the intestines. IBS may lead to a significant reduction in the production of butyric acid by bacteria in the large intestine, thereby causing symptoms like constipation, diarrhoea and abdominal pain. Energast has been clinically proven to relieve patients from such symptoms due to its patented micro-encapsulated formulation of sodium butyrate.
There are reasons why our intestines could produce less butyric acid than required. One reason is that we do not take sufficinet daily fibre. Another reason may be an imbalance of butyrogenic bacteria (butyric acid producing bacteria) due to antibiotics or intestinal infection of age or inflammation. Irritable bowel syndrome (IBS) may also result in changes in the microbial environment of the large intestines, resulting in a lack of butyric acid production.
Lack of butyric acid can cause symptoms like :
Clinical trials have confirmed that Energast (micro-encapsulated sodium butyrate) as dietary management in patients with irritable bowel syndrome reduces disease symptoms and improves the quality of life. The absence of side effects indicates that Energast is safe and well-tolerated as a dietary management in patients with IBS.
Clinical trials confirm the benefits of Energast :
The Energast capsule is specifically formulated to release the active ingredient gradually thoughout the intestines which allows the sodium butyrare to be absorbed all along the intestines and colon.
First product based on SCFAs (short chain fatty acids)
- The one and only original protected sodium butyrate preparation
- Patent protected innovative formulation
- Sustained and targeted intestine release
- The efficacy confirmed in clinical studies